Risk stratification of patients with chest pain has traditionally focused on identifying obstructive coronary artery disease (CAD). Using this traditional approach, many symptomatic individuals are ...

Cardiovascular diseases (CVDs) are the leading cause of non-communicable disease (NCD) deaths in India, accounting for nearly ...

Adding the PCSK9 inhibitor evolocumab to a high-intensity, cholesterol-lowering regimen reduced the risk of a first major ...

Two newly developed tools for predicting 10-year risk of cardiovascular mortality in patients with established atherosclerotic cardiovascular disease (ASCVD) outperform a model commonly used to assess ...

The Family Heart Foundation, a non-profit research and advocacy organization to lead research and education, focusing on genetic dyslipidemias, has launched the Lp(a) AW(a)RE initiative to engage key ...

Results from the international VESALIUS-CV (TIMI 66) clinical trial found that among adults with atherosclerotic cardiovascular disease (ASCVD) or diabetes and no history of a prior heart attack or ...

Any aspirin use linked to lower hazards of MI, ischemic stroke, with greater benefit in high-frequency use group.

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial ...

Detailed price information for Arrowhead Pharma (ARWR-Q) from The Globe and Mail including charting and trades.

The Family Heart Foundation, the leading research, education and advocacy organization focused on genetic dyslipidemias, has ...